Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Pitolisant -- A...

    Pitolisant -- A promising drug for narcolepsy

    Written by Medha Baranwal Baranwal Published On 2018-09-23T20:10:29+05:30  |  Updated On 23 Sept 2018 8:10 PM IST
    Pitolisant -- A promising drug for narcolepsy

    New longer-term data from the Harmony III open-label study presented at the 7th International Symposium on Narcolepsy in Beverly, Massachusetts, provides more evidence that the Harmony Biosciences' investigational drug pitolisant reduces excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy.


    Pitolisant is the first-in-class medication with a novel mechanism of action. "It works as a selective histamine 3 (H3) receptor antagonist/inverse agonist that enhances the activity of histaminergic neurons in the brain, which have been shown to improve a patient's wakefulness and inhibits attacks of cataplexy," Dr. Jeffrey Dayno, Harmony's chief medical officer, said in the company's press release.


    Narcolepsy is a rare, chronic, debilitating neurologic disorder of sleep-wake state instability and is primarily characterized by excessive daytime sleepiness, cataplexy, and other manifestations of REM sleep dysregulation, which intrude into wakefulness. In most patients, it is caused by the loss of hypocretin, a neuropeptide in the brain that supports sleep-wake state stability. This disorder affects men and women equally with typical symptom onset in adolescence or young adulthood; however, it can take up to a decade to be properly diagnosed.


    "The Harmony III open-label, long-term study for pitolisant reflects real-world experience of people living with the debilitating effects of excessive daytime sleepiness and cataplexy in narcolepsy."


    Of 77 patients invited to participate in the extension period up to five years, 50 patients (65%) completed the first 12-month period, 48 elected to participate in the extension period and 32 of those (67%) stayed on pitolisant for five years or until the study ended. Most were maintained on pitolisant 40 mg once daily.


    Key Findings of the Trial:

    • Patients continuing on pitolisant saw continued improvement in EDS based on the Epworth Sleepiness Scale (ESS).

    • The baseline ESS was 16.8, decreased to 13.4 at year one, then continued to improve over the course of the study with an ESS of 10.6 at five years.

    • Symptoms of REM dysregulation were reduced from baseline to year one as follows: cataplexy (-76%), hypnagogic hallucinations (-54%) and sleep paralysis (-62%). However, limited data from patient diaries were available at year 5 to assess these symptoms.

    • The safety and tolerability of pitolisant in the open-label study mirrored that seen in the randomized controlled trials for pitolisant.

    • Common side effects were headache, insomnia, weight gain, anxiety, depression, nausea, vomiting, and irritability; 16% of patients discontinued treatment due to adverse events.

    • There was no evidence of the development of tolerance with long-term use of pitolisant and there were no reports of withdrawal symptoms when the drug was stopped.


    There was no evidence of the development of tolerance with long-term use of pitolisant and there were no reports of withdrawal symptoms when the drug was stopped.


    "As pitolisant is not yet approved in the U.S., we cannot comment on the efficacy and safety of pitolisant as compared to other products on the market," said Dr. Dayno.


    Pitolisant has received orphan, breakthrough-therapy and fast-track designations by the U.S. Food and Drug Administration (FDA) for the treatment of EDS and cataplexy in narcolepsy.


    "If approved, pitolisant would represent the first new therapy in the U.S. in over a decade for the treatment of both EDS and cataplexy in patients with narcolepsy," said Dr. Dayno. Pitolisant was approved in Europe in 2016 for adults with narcolepsy with or without cataplexy. "Harmony's goal is to obtain FDA approval to market this new medication in the U.S. in 2019."


    For further reference follow the link: https://bit.ly/2NUKp5Y
    cataplexydaytimedysregulationexcessiveHarmony BiosciencesHarmony IIIinsomniaInternational Symposium on NarcolepsyJeffrey DaynonarcolepsypitolisantREMSleepSleepiness
    Source : With inputs from International Symposium on Narcolepsy

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok